Lantern Pharma Inc. (LTRN): Price and Financial Metrics
LTRN Price/Volume Stats
Current price | $9.65 | 52-week high | $11.99 |
Prev. close | $9.78 | 52-week low | $2.38 |
Day low | $9.65 | Volume | 1,146 |
Day high | $9.65 | Avg. volume | 258,793 |
50-day MA | $5.63 | Dividend yield | N/A |
200-day MA | $4.54 | Market Cap | 103.65M |
LTRN Stock Price Chart Interactive Chart >
Lantern Pharma Inc. (LTRN) Company Bio
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Latest LTRN News From Around the Web
Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.
The 3 Most Undervalued AI Penny Stocks to Buy in DecemberIt’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023. The AI market was worth roughly $515 billion in 2023. By 2030, it is expected to more than quadruple in value, reaching $2.025 trillion. That equates to a compound annual growth rate of more than 21% over the period. So, it’s easy to see why investors are scrambling to invest in undervalued penny in the |
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)DALLAS, November 30, 2023--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284. |
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call TranscriptLantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast […] |
LTRN: Three Assets in the Clinic in 3Q:23By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Third Quarter 2023 Financial and Operational Results On November 8, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:23 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. Since Lantern’s second quarter update, it has added new sites in Asia for its |
Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational UpdatesAdvancements in Clinical Trials and AI Platform Highlighted Amid Financial Discipline |
LTRN Price Returns
1-mo | 114.44% |
3-mo | 125.47% |
6-mo | 182.99% |
1-year | 108.87% |
3-year | -46.66% |
5-year | N/A |
YTD | 125.47% |
2023 | -29.14% |
2022 | -24.31% |
2021 | -58.55% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...